Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

IMPORTANCE: Nivolumab, a monoclonal antibody that inhibits programmed cell death 1, is approved by the US Food and Drug Administration for treating advanced melanoma, renal cell carcinoma (RCC), non–small cell lung cancer (NSCLC), and other malignancies. Data on long-term survival among patients rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Topalian, Suzanne L., Hodi, F. Stephen, Brahmer, Julie R., Gettinger, Scott N., Smith, David C., McDermott, David F., Powderly, John D., Sosman, Jeffrey A., Atkins, Michael B., Leming, Philip D., Spigel, David R., Antonia, Scott J., Drilon, Alexander, Wolchok, Jedd D., Carvajal, Richard D., McHenry, M. Brent, Hosein, Fareeda, Harbison, Christopher T., Grosso, Joseph F., Sznol, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659167/
https://www.ncbi.nlm.nih.gov/pubmed/31343665
http://dx.doi.org/10.1001/jamaoncol.2019.2187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659167/
https://www.ncbi.nlm.nih.gov/pubmed/31343665
http://dx.doi.org/10.1001/jamaoncol.2019.2187

Ejemplares similares